Lighthouse Pharmaceuticals Raises $12M in Series A Funding

The company plans to use the funds to advance its lead program, LHP588, and continue expanding its pipeline.

Lighthouse is running the SPRING clinical trial, a Phase 2 study testing LHP588 in patients with mild to moderate Alzheimer’s disease who are positive for P. gingivalis. The trial is also supported by a $49.2 million grant from the National Institute on Aging, part of the National Institutes of Health.

The SPRING trial is a double masked, placebo controlled study evaluating LHP588 a once daily oral treatment targeting P. gingivalis a bacterium linked to gum disease and increasingly associated with the development of Alzheimers disease. The study is currently enrolling participants across the United States.

"Lighthouse is advancing a differentiated approach based on compelling scientific, and clinical data. This financing, together with the support from the NIA gives Lighthouse the resources to efficiently execute the SPRING trial and advance LHP588 toward late stage development," said Casey Lynch, Chief Executive Officer of Lighthouse Pharmaceuticals. "By targeting a defined subset of Alzheimer's disease we aim to bring a more precise and effective therapeutic approach to patients."

Read More:Windmill Raises $12M in Funding Led by Inspired Capital

"Lighthouse is pursuing a distinctive and focused approach in Alzheimer's disease," said Campbell Murray. "With LHP588, the company is targeting an important and underexplored biological driver in a defined patient population. We believe the SPRING trial has the potential to generate clinically meaningful data and further establish Lighthouse as an innovative company in neurodegeneration."

About Lighthouse Pharmaceuticals

Founded by Casey Lynch and Michael Detke, Lighthouse Pharmaceuticals develops new small molecule treatments for chronic neurological, and inflammatory diseases. Its main program focuses on Alzheimer’s disease, including the ongoing SPRING clinical trial.

Read More:OpenLight Raises $50M in Series A-1 Funding